An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

Stopped early · Phase 2

Conditions studied: Hyperkalemia

In brief

This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.

Key facts

Study ID

NCT02033317

Run by

Relypsa, Inc.

People needed

6

Starts

2008-08-01

Expected to finish

2008-12-01

Last updated by the study team

2021-05-12

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants on hemodialysis between the ages of 18 and 70 years, with serum potassium levels of at least 5.5 mmol/L
• Adequately dialyzed (Kt/V ≥ 1.2)

You may not qualify if…

• History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders or major gastrointestinal surgery.
• Severe constipation or irregular bowel habits.
• Unable to consume or tolerate the study-specific diet.

Where it is running

• Investigator Site — Orlando, Florida, United States
• Investigator Site — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.